{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:25:23Z","timestamp":1772429123298,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2015,7,4]]},"DOI":"10.1080\/19420862.2015.1040973","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T14:49:08Z","timestamp":1431355748000},"page":"653-661","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Regulatory considerations in oncologic biosimilar drug development"],"prefix":"10.1080","volume":"7","author":[{"given":"Judith C","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira A","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,5,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.03.008"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01566.x"},{"key":"cit0003","first-page":"819","volume":"65","author":"Mounho B","year":"2010","journal-title":"Food Drug Law J"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.2165\/11593730-000000000-00000"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3390\/ph5040353"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0020-y"},{"key":"cit0007","volume-title":"Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies\u2014Non-clinical and Clinical Issues [Internet]","author":"European Medicines Agency","year":"2012"},{"key":"cit0008","volume-title":"Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use [Internet]","author":"European Medicines Agency","year":"2012"},{"key":"cit0009","volume-title":"Guideline on Good Pharmacovigilance Practices [Internet]","author":"European Medicines Agency","year":"2013"},{"key":"cit0010","volume-title":"Title VII\u2014Improving Access to Innovative medical Therapies. Subtitle A\u2014Biologics Price Competition and Innovation Act, 2009 [Internet]","author":"US Food and Drug Administration","year":"2009"},{"key":"cit0011","volume-title":"Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, Draft Guidance [Internet]","author":"US Food and Drug Administration","year":"2012"},{"key":"cit0012","volume-title":"Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, Draft Guidance [Internet]","author":"US Food and Drug Administration","year":"2012"},{"key":"cit0013","volume-title":"Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product, Draft Guidance [Internet]","author":"US Food and Drug Administration","year":"2014"},{"key":"cit0014","volume-title":"Guidance for Industry: Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants, Draft Guidance","author":"US Food and Drug Administration","year":"2013"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29848"},{"key":"cit0017","unstructured":"US Food and Drug Administration. Biosimilar User Fee Act (BsUFA) [Internet]. Silver Springs, MD: US Food and Drug Administration; 2012 [updated 2014 Aug 8; cited 2014 Dec 2]. Available at: http:\/\/www.fda.gov\/ForIndustry\/UserFees\/BiosimilarUserFeeActBsUFA\/default.htm."},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.2147\/BS.S38572"},{"key":"cit0019","volume-title":"World Health Organization","author":"Expert Committee on Biological Standardization","year":"2009"},{"key":"cit0020","volume-title":"VII Conference of the Pan American Network for Drug Regulatory Harmonization (PANDRH) [Internet]. Proceedings of the VII PANDRH Conference Sessions","author":"World Health Organization"},{"key":"cit0021","volume-title":"IFPMA Policy Statement: Non-comparable Biotherapeutic Products [Internet]","author":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)","year":"2014"},{"key":"cit0023","volume-title":"Biosimilar Medicines [Internet]","author":"European Medicines Agency","year":"2005"},{"key":"cit0024","volume-title":"Consensus Information Paper, 2013: What You Need to Know About Biosimilar Medicinal Products: Process on Corporate Responsibility in the Field of Pharmaceuticals Access to Medicines in Europe. A Consensus Information Document","author":"European Commission","year":"2013"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2014.0302.018"},{"key":"cit0026","volume-title":"Administrative Ordinance\/Instructions. Authorisation of similar biological medicinal products (Biosimilars) [Internet]","author":"Swissmedic","year":"2014"},{"key":"cit0027","volume-title":"Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) [Internet]","author":"Health Canada","year":"2008"},{"key":"cit0028","volume-title":"Evaluation of Biosimilars, Version 1.0 [Internet]","author":"Office of Medicines Authorisation","year":"2013"},{"key":"cit0029","volume-title":"EBE Position Paper on Labelling of Biosimilars\u2014Summary of Product Information Characteristics (SmPC) and Patient Information Leaflet (PIL) \u2013 Draft April 2013","author":"European Biopharmaceutical Enterprises","year":"2013"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2014.0304.043"},{"key":"cit0031","volume-title":"Guidance Agenda: New & Revised Draft Guidances CDER Is Planning to Publish During Calendar Year 2014 [Internet]","author":"US Food and Drug Administration","year":"2014"},{"key":"cit0032","volume-title":"Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products: a Proposed Rule by the Food and Drug Administration [Internet]","author":"US Food and Drug Administration, Department of Health and Human Services","year":"2013"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.187"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2447"},{"key":"cit0035","volume-title":"European Public Assessment Reports: Inflectra (infliximab) EPAR\u2013Product Information [Internet]","author":"European Medicines Agency","year":"2013"},{"key":"cit0036","volume-title":"European Public Assessment Report: Remsima (infliximab) EPAR\u2013Summary for the Public [Internet]","author":"European Medicines Agency","year":"2013"},{"key":"cit0037","volume-title":"Remsima\u2013Summary Basis of Decision [Internet]","author":"Health Canada","year":"2014"},{"key":"cit0038","volume-title":"WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products [Internet]","author":"World Health Organization","year":"2006"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.2146\/news140023"},{"key":"cit0040","volume-title":"Naming of Biosimilars [Internet]","author":"Generic Pharmaceutical Association","year":"2014"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.783560"},{"key":"cit0044","volume-title":"Guideline for the Quality, Safety, and Effectiveness of Biosimilar Products [Internet]","author":"The Pharmaceuticals and Medical Devices Agency, Japan","year":"2009"},{"issue":"2","key":"cit0045","volume":"23","author":"World Health Organization","year":"2009","journal-title":"WHO Drug Information"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.230"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425744"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.68"},{"key":"cit0049","volume-title":"Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) [Internet]","author":"World Health Organization","year":"2009"},{"key":"cit0050","unstructured":"World Health Organization. Regulatory Expectations and Risk Assessment for Biotherapeutic Products: Scientific Principles to Consider: Draft [Internet]. 2014 Jan [cited 2014 Dec 1]. Available at: http:\/\/www.who.int\/biologicals\/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf"},{"key":"cit0052","volume-title":"Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations [Internet]","author":"US Food and Drug Administration","year":"2014"},{"key":"cit0053","first-page":"30","volume":"33","author":"Vivian JC","year":"2008","journal-title":"US Pharm"},{"key":"cit0054","volume-title":"Background Information: Lists of Licensed Biological Products With Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations [Internet]","author":"US Food and Drug Administration","year":"2014"},{"key":"cit0055","volume-title":"Possibility of Substitution of Biosimilars in Europe [Internet]","author":"Generics and Biosimilars Initiative","year":"2014"},{"key":"cit0056","volume-title":"France to Allow Substitution of Biosimilars [Internet]","author":"Generics and Biosimilars Initiative","year":"2014"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt325"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2015.1040973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:39:29Z","timestamp":1481848769000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2015.1040973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,11]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,5,27]]},"published-print":{"date-parts":[[2015,7,4]]}},"alternative-id":["10.1080\/19420862.2015.1040973"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2015.1040973","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}